Could Aimmune Therapeutics Inc (NASDAQ:AIMT) Go Up After Its Newest Short Interest Report?

June 17, 2018 - By Hazel Jackson

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Logo

The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) registered an increase of 9.49% in short interest. AIMT’s total short interest was 4.91M shares in June as published by FINRA. Its up 9.49% from 4.49 million shares, reported previously. With 409,700 shares average volume, it will take short sellers 12 days to cover their AIMT’s short positions. The short interest to Aimmune Therapeutics Inc’s float is 17.55%.

The stock increased 2.38% or $0.71 during the last trading session, reaching $30.49. About 611,396 shares traded or 5.41% up from the average. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has risen 78.81% since June 17, 2017 and is uptrending. It has outperformed by 66.24% the S&P500.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.77 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

More notable recent Aimmune Therapeutics, Inc. (NASDAQ:AIMT) news were published by: Seekingalpha.com which released: “Aimmune Therapeutics: Special Situation Biotech Opportunity” on June 08, 2018, also Seekingalpha.com with their article: “Rounds Report: Aimmune Is Gaining Momentum While Editas Experiences Significant Insider Purchases” published on May 24, 2018, Streetinsider.com published: “Aimmune Therapeutics (AIMT) Names Dr. Jayson Dallas as CEO” on June 11, 2018. More interesting news about Aimmune Therapeutics, Inc. (NASDAQ:AIMT) were released by: Nasdaq.com and their article: “New Research Coverage Highlights Avery Dennison, Raymond James Financial, Genuine Parts, Kimco Realty, Bristow …” published on June 15, 2018 as well as Seekingalpha.com‘s news article titled: “Aimmune Nearing Critical Point In Valuation” with publication date: May 20, 2018.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: